Lukas Bissegger

4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Chiara Borsari, Erhan Keleş, Denise Rageot et al. · Journal of Medicinal Chemistry · 2020 · 22 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα

Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer et al. · Chemical Science · 2023 · 20 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor

Martina De Pascale, Lukas Bissegger, Chiara Tarantelli et al. · European Journal of Medicinal Chemistry · 2022 · 16 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14